• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lisata Therapeutics, Inc. - Common Stock (NQ: LSTA )

    3.660 UNCHANGED
    Streaming Delayed Price Updated: 12:43 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 45,451
    Open 3.610
    Bid (Size) 3.610 (1)
    Ask (Size) 3.850 (20)
    Prev. Close 3.660
    Today's Range 3.500 - 3.690
    52wk Range 1.950 - 3.870
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
    From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
    Via GlobeNewswire
    EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
    Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing... 
    Via Benzinga

    Performance

    YTD
    +31.65%
    +31.65%
    1 Month
    +6.40%
    +6.40%
    3 Month
    +31.65%
    +31.65%
    6 Month
    +24.49%
    +24.49%
    1 Year
    -2.40%
    -2.40%

    More News

    Read More
    Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Recap: Lisata Therapeutics Q4 Earnings
    Via Benzinga
    Earnings Scheduled For February 29, 2024
    Via Benzinga
    Lisata Therapeutics's Earnings Outlook
    Via Benzinga
    Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
    Via News Direct
    Exposures Product Safety
    Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
    Via TheNewswire.com
    Exposures Product Safety
    LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
    From Virtual Investor Conferences
    Via GlobeNewswire
    Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ
    From Virtual Investor Conferences
    Via GlobeNewswire
    Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
    From Lisata Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.